ReviewNature reviews. Urology2012
Isolated, disseminated and circulating tumour cells in prostate cancer.
Review in Nature reviews. Urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Amorphous calcium phosphate-coated surfaces as a model for bone microenvironment in prostate cancer.Heliyon · 2025Article
- Prognostic prediction signature and molecular subtype for liver cancer: A CTC/CTM‑related gene prediction model and independent external validation.Oncology letters · 2024Article
- PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.Oncogene · 2024Article
- Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.International journal of molecular sciences · 2022Review
- Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer.Biomedicines · 2021Article
- CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance.Scientific reports · 2021Article
- Cancer stem cells in breast and prostate: Fact or fiction?Advances in cancer research · 2019Review
- Entrapment of Prostate Cancer Circulating Tumor Cells with a Sequential Size-Based Microfluidic Chip.Analytical chemistry · 2018Article
- Emerging and Established Models of Bone Metastasis.Cancers · 2018Review
- Review
- Liquid biopsy for pediatric central nervous system tumors.NPJ precision oncology · 2018Review
- Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis.Stem cells international · 2017Review
- Article
- High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.The Journal of molecular diagnostics : JMD · 2016Article
- Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.PloS one · 2014Article
- Article
- MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells.Cell death & disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The loss of single cells from a tumour cell cluster marks an early event in the metastatic process of cancer progression. Although the metastatic cascade in prostate cancer is yet to be fully understood, monitoring circulating tumour cells (CTCs) and quantifying the load of tumour cell dissemination is currently being implemented into routine clinical practice for diagnosing minimal residual disease (MRD), estimating prognosis and monitoring treatment success. Current methods for enrichment of CTCs or disseminated tumour cells (DTCs) and detection of MRD rely on the expression of specific marker genes or proteins that might be altered during the process of tumour cell dissemination, therefore disrupting tumour cell detection. The tumour origin and malignant potential for metastasis of marker-positive cells is not yet clear. Some studies have demonstrated the potential of CTCs or DTCs as prognostic or predictive markers, leading to the increasing implementation of CTC measurement as an end point in clinical trials.
Indexed as
Identifiers
22777287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.